CONSERVE Plus Post-Approval Study (PAS)

This study has been terminated.
Information provided by (Responsible Party):
MicroPort Orthopedics Inc. Identifier:
First received: May 2, 2011
Last updated: October 24, 2014
Last verified: October 2014
The objective of this post-approval study is to provide scientifically valid and reliable evidence that supports claims of longer term safety and effectiveness with regard to Month 120 device survivorship rates.

Other and Unspecified Injury to Hip and Thigh

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Conserve Plus Total Hip Resurfacing System: A Non-Randomized, Multi-center, NewEnrollement Post Approval Study

Further study details as provided by MicroPort Orthopedics Inc.:

Primary Outcome Measures:
  • Clinical success at Month 120 [ Time Frame: 10 years ] [ Designated as safety issue: Yes ]
    Clinical success at Month 120 for each patient will be survivorship, defined as freedom from revision or removal for any aseptic reason and at least "good" function/pain relief defined as Harris Hip Score ≥ 80.

Secondary Outcome Measures:
  • Radiographic outcomes [ Time Frame: 10 years ] [ Designated as safety issue: Yes ]
    Secondary measures: radiographic outcomes

  • Metal Ion (serum) [ Time Frame: 24 months ] [ Designated as safety issue: Yes ]
    metal ion (serum) and renal function will also be collected.

  • Assessment for Adverse Events [ Time Frame: 10 years ] [ Designated as safety issue: Yes ]
    Subjects will be assessed for any adverse events during their length of participation

  • Measurement of Patient Satisfaction [ Time Frame: 10 years ] [ Designated as safety issue: No ]
    Patient satisfaction as assessed by the SF-12

Enrollment: 199
Study Start Date: November 2010
Study Completion Date: September 2014
Primary Completion Date: September 2014 (Final data collection date for primary outcome measure)
CONSERVE® Plus hip resurfacing
Recipients/C Plus (IDE)study

Detailed Description:
This study will evaluate the performance of CONSERVE Plus Hip Resurfacing System under actual conditions of use. Additionally, this study will evaluate the performance of the device in the post approval environment to see if there are any significant changes in device performance as compared to the pre-market IDE Study

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients who have already undergone hip resurfacing in the CONSERVE Plus IDE.

Inclusion Criteria:

  1. Was previously enrolled in the CONSERVE® Plus IDE as part of the All Enrolled Audited Cohort (N=1366 procedures (1206 patients)) and received the "Original Shell".
  2. Is willing and able to comply with the study plan and able to understand and sign the Patient Informed Consent Form.

Exclusion Criteria:

  1. Patient is mentally incompetent.
  2. Patient is a prisoner.
  3. Patient is an alcohol and/or drug abuser
  4. Patient has undergone device revision or removal
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01367899

United States, North Carolina
Michael Bolognesi, MD
Durham, North Carolina, United States, 27705
Sponsors and Collaborators
MicroPort Orthopedics Inc.
Principal Investigator: Michael Bolognesi, MD Duke University
  More Information

Responsible Party: MicroPort Orthopedics Inc. Identifier: NCT01367899     History of Changes
Other Study ID Numbers: 09-LJH-002 
Study First Received: May 2, 2011
Last Updated: October 24, 2014
Health Authority: United States: Institutional Review Board

Keywords provided by MicroPort Orthopedics Inc.:
Efficacy processed this record on May 23, 2016